amifostine anhydrous and prednisone

amifostine anhydrous has been researched along with prednisone in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E	1
Budach, V; Eucker, J; Genvresse, I; Krüger, L; Lange, C; Possinger, K; Schweigert, M; Sezer, O; Späth-Schwalbe, E	1
Campana, F; Casanova, L; Casteñeda, CA; de Mendoza, FH; Flores, C; Gómez, HL; Leon, J; Neciosup, SP; Pinto, JA; Samanéz, C; Vallejos, CS; Vera, L	1

Reviews

1 review(s) available for amifostine anhydrous and prednisone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for amifostine anhydrous and prednisone

Article	Year
Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study. Anti-cancer drugs, 2002, Volume: 13, Issue:4 Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytoprotection; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Treatment Outcome; Vincristine	2002
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Hematology/oncology and stem cell therapy, 2012, Volume: 5, Issue:3 Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Neutropenia; Prednisone; Prognosis; Radiation-Protective Agents; Vincristine	2012

Article

Year

Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.

Anti-cancer drugs, 2002, Volume: 13, Issue:4

Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytoprotection; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Treatment Outcome; Vincristine

2002

Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.

Hematology/oncology and stem cell therapy, 2012, Volume: 5, Issue:3

Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Neutropenia; Prednisone; Prognosis; Radiation-Protective Agents; Vincristine

2012

Other Studies

2 other study(ies) available for amifostine anhydrous and prednisone

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anti-cancer drugs, 2001, Volume: 12, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine	2001

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.

Anti-cancer drugs, 2001, Volume: 12, Issue:4

Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine

2001